Quick Takeaways
- This page summarizes Barbara Gayle Duncan's Form 4 filing for Ovid Therapeutics Inc. (OVID).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 18 May 2021, 20:57.
Barbara Gayle Duncan - 17 May 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)
- Role
- Director
- Signature
- /s/ Danielle Mann for Barbara Gayle Duncan by PoA
- Issuer symbol
- OVID
- Transactions as of
- 17 May 2021
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 18 May 2021, 20:57:18 UTC
- Next filing
- 07 Jun 2021
- SEC
- View on sec.gov
Quoteable Key Fact
"Barbara Gayle Duncan filed Form 4 for Ovid Therapeutics Inc. (OVID) on 18 May 2021."
What Changed
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OVID | Stock Option (Right to Buy) | Award | $0 | +1,750 | $0.000000 | 1,750 | 17 May 2021 | Common Stock | 1,750 | $3.67 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option will vest in full on June 5, 2021, subject to the Reporting Person's continuous service through such vesting date. |